Chimeric antigen receptors for treating myeloid malignancies - Patents.com
JP7652396B2Active Publication Date: 2025-03-27H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC +1
5 Cites 0 Cited by
Patent Information
- Application Number
- JP2022509576
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-08-16
- Filing Date
- 2020-08-14
- Publication Date
- 2025-03-27
- Estimated Expiration
- 2040-08-14
AI Technical Summary
Benefits of technology
【0072】 本発明の1つ以上の実施形態の詳細を添付の図面及び以下の説明で示す。本発明の他の特性、目的及び利点は、記載及び図面並びに特許請求の範囲から明らかとなるであろう。
✦ Generated by Eureka AI based on patent content.
Abstract
Compositions and methods for treating acute myeloid leukemia (AML) in a subject are disclosed. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to treat AML. Also disclosed are immune effector cells, such as T cells or natural killer (NK) cells, that are modified to express these CARs. Accordingly, also disclosed are methods of treating AML in a subject that involve adoptive transfer of the disclosed immune effector cells that have been modified to express the disclosed CARs.
Need to check novelty before this filing date? Find Prior Art